DiaMedica Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-32.8M | $-24.4M | $-19.4M | $-13.7M | $-13.6M | $-12.3M | $-10.6M | $-5.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $43.0K | $39.0K | $30.0K | $25.0K | $24.0K | $21.0K | $21.0K | $15.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.8M | $2.1M | $1.7M | $1.5M | $1.6M | $1.8M | $1.2M | $620.0K |
| Net Cash from Operating Activities | $-29.1M | $-22.1M | $-18.7M | $-11.5M | $-12.3M | $-9.2M | $-9.1M | $-5.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $40.0K | $25.0K | $24.0K | $81.0K | $22.0K | $47.0K | $2.0K | $50.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-2.2M | $8.6M | $-18.3M | $11.5M | $-20.5M | $-16.1M | $-3.9M | $-50.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $43.9M | $12.0M | $36.8M | $-6.0K | $30.1M | $28.8M | $70.0K | $21.2M |
| Net Change in Cash | $12.6M | $-1.5M | $-185.0K | $21.0K | $-2.7M | $3.5M | $-12.9M | $15.5M |
| Free Cash Flow | $-29.1M | $-22.1M | $-18.8M | $-11.6M | $-12.3M | $-9.2M | $-9.1M | $-5.7M |